


## Journal Pre-proof

Chemo- and biocatalytic esterification of marchantin A and cytotoxic activity of ester derivatives

Miroslav Novakovic, Stefan Simić, Ljiljana Koračak, Mario Zlatović, Tatjana Ilic-Tomic, Yoshinori Asakawa, Jasmina Nikodinovic-Runic, Igor Opsenica



PII: S0367-326X(20)30102-7

DOI: <https://doi.org/10.1016/j.fitote.2020.104520>

Reference: FITOTE 104520

To appear in: *Fitoterapia*

Received date: 21 January 2020

Revised date: 19 February 2020

Accepted date: 19 February 2020

Please cite this article as: M. Novakovic, S. Simić, L. Koračak, et al., Chemo- and biocatalytic esterification of marchantin A and cytotoxic activity of ester derivatives, *Fitoterapia* (2020), <https://doi.org/10.1016/j.fitote.2020.104520>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

## **Chemo- and Biocatalytic Esterification of Marchantin A and Cytotoxic Activity of Ester Derivatives**

Miroslav Novakovic,<sup>a,\*</sup> Stefan Simić,<sup>b</sup> Ljiljana Koračak,<sup>b</sup> Mario Zlatović,<sup>b</sup> Tatjana Ilic-Tomic,<sup>c</sup> Yoshinori Asakawa,<sup>d</sup> Jasmina Nikodinovic-Runic,<sup>c,\*</sup> Igor Opsenica<sup>b,\*</sup>

<sup>a</sup> National Institute, Institute of Chemistry, Technology and Metallurgy, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia

<sup>b</sup> University of Belgrade-Faculty of Chemistry, Studentski trg 16, P. O. Box 51, 11158 Belgrade, Serbia

<sup>c</sup> Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11000 Belgrade, Serbia

<sup>d</sup> Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan

## Abstract

Chemical and biocatalytic synthesis of seven previously undescribed marchantin A ester derivatives has been presented. Chemical synthesis afforded three peresterified bisbibenzyl products (**TE1-TE3**), while enzymatic method, using lipase, produced regioselective monoester derivatives (**ME1-ME4**). The antiproliferative activities of all prepared derivatives of marchantin A were tested on MRC5 healthy human lung fibroblast, A549 human lung cancer, and MDA-MB-231 human breast cancer cell lines. All tested esters were less cytotoxic in comparison to marchantin A, but they also exhibited lower cytotoxicity against healthy cells. Monoesters displayed higher cytotoxic activities than the corresponding peresterified products, presumably due to the presence of free catechol group. Monohexanoyl ester **ME3** displayed the same  $IC_{50}$  like marchantin A against MDA-MB-231 cells, but the selectivity was higher. In this way, regioselective enzymatic monoesterification enhanced selectivity of marchantin A. **ME3** was also the most active among all derivatives against lung cancer cells A549 with the slightly lower activity and selectivity in comparison to marchantin A.

## Keywords

marchantin A, lipase, esterification, cytotoxicity, lung and breast cancer cell lines

\*Corresponding authors

*E-mail addresses:* mironov@chem.bg.ac.rs; mironov76@yahoo.com (M. Novakovic);  
jasmina.nikodinovic@imgc.bg.ac.rs (J. Nikodinovic-Runic); igorop@chem.bg.ac.rs (I. Opsenica)

## 1. Introduction

Taxonomically positioned between algae and vascular plants, liverworts belong to an early-diverging lineage of land plants, and are considered the simplest of terrestrial plants (Quang and Asakawa, 2010; Asakawa et al., 2013; Ludwiczuk and Asakawa, 2014; Tanaka et al., 2016). Within oil bodies, intracellular membrane-bound organelles, liverworts contain numerous terpenes and lipophilic aromatics (Asakawa, 1982, 1995; Asakawa et al., 2013; He et al., 2013; Novakovic et al., 2019). Bisbibenzyls are plant metabolites characteristically found in liverworts with a single exception represented by the isolation of Riccardin C from a different plant division, namely *Primula macrocalyx* Bge. (*Primulaceae*) (Kocenkova et al., 2007). Apart from their chemotaxonomic importance, bisbibenzyls display various biological activities. Among the known bisbibenzyls, Marchantin A is the most investigated, and has been reported to have cytotoxic (Gaweł-Bęben et al., 2019; Huang et al., 2016; Jensen et al., 2012; Osei-Safo et al., 2017), antiprotozoal (S. Jensen et al., 2012; Otoguro et al., 2012), vasorelaxant (Morita et al., 2011), antibacterial (Asakawa 1990; Kámory et al., 1995), anti-influenza activity (Iwai et al., 2011), as well as lipopolysaccharide-induced NCS (Harinantenaina et al., 2005), and 5-lipoxygenase and cyclooxygenase inhibitory activity (Asakawa 1990; Schwartner et al., 1995).

Lipophilicity is an important physicochemical property in drug discovery, affecting pharmaceutical, pharmacokinetic, and pharmacodynamic action of the active molecule. Namely, it influences several stages of drug action, including transport through cell membranes, binding to the target as well as ADMET (absorption, distribution, metabolism, excretion, toxicity) properties (Rutkowska et al., 2013). In accordance with this, it has been reported that increasing the lipophilicity of various target molecules (e.g. by acylation) results in an increase in hypoglycemic (Li et al., 2012), antioxidant (Candiracci et al., 2016), and antitumor activities (Facchetti et al., 1991; Maliepaard et al., 1992).

In this work, we report a chemical and biocatalytic synthesis of seven new marchantin A esters. Additionally, the anti-proliferative activities of all of the prepared derivatives of marchantin A were tested on MRC-5 healthy human fibroblast, A549 human lung cancer, and MDA-MB-231 breast cancer cell lines.

## 2. Results and discussion

### 2.1. Synthesis

The conversion of marchantin A into corresponding esters of several aliphatic carboxylic acids was envisaged in order to investigate the effect of increased lipophilicity on cytotoxic activity. Firstly, a base-promoted transesterification employing three vinyl esters (Table 1) was undertaken. An excess of vinyl esters was used, in the presence of sodium carbonate, in acetonitrile, at 120 °C. The applied reaction conditions afforded exclusively triacylated derivatives of marchantin A (**TE1-TE3**) in good to excellent yields, requiring no further purification. Additionally, in order to test the outcome of an acid-promoted transesterification Amberlyst 15 and vinyl propionate were used in acetonitrile, at 120 °C. A more complex reaction mixture was observed compared to the one performed in base-promoted conditions, and quantitative NMR analysis revealed that the corresponding triacylated product was obtained in 40% yield (using methyl benzoate as a standard).

Table 1.

Since no regioselectivity was observed in the previously described conditions, a method allowing partial esterification of marchantin A was sought thereafter. A literature search concerned with regioselective acylation revealed lipases as promising catalysts. Namely, lipases (EC 3.1.1.3) catalyze the hydrolysis of triglycerides, and are classified as hydrolase enzymes. They are produced ubiquitously by plants, animals, insects and microbes, the last of which represents the most common source of lipase due to ease of culture handling, availability and scale-up scope (Sarmah et al., 2018). Their applications range from oleochemistry (Abdelmoez and Mustafa, 2014; Hama and Noda, 2018), detergent (Jurado et al., 2011; Soleimani et al., 2017) and food industries (Ferreira-Dias et al., 2013), to the preparation of chiral intermediates (de Miranda, 2015; Seddigi et al., 2017). Relevant to the scope of this work, lipases were also demonstrated to perform regioselective acylation (Lee et al., 2019; Wang et al., 2018; Yang et al., 2014) as well as hydrolysis (Carey and McCann, 2019). As a catalyst of choice for the esterification of marchantin A, Novozym® 40086 was selected. The reaction was initially tested with the excess of vinyl propionate, in *i*-Pr<sub>2</sub>O at 45 °C (Table 2, entry 1). After 24 h, complete consumption of the starting material was observed by thin-layer chromatography, along with the formation of the complex reaction mixture. NMR analysis of the crude reaction mixture confirmed the complete consumption of the starting material and revealed three signals corresponding to the H-3',

suggesting that there may be three substituted marchantin A products (see supporting information). The dominant product was isolated and purified by preparative thin-layer chromatography, and structural analysis revealed that monosubstitution of marchantin A had taken place, on the 13-OH. Comparison of the  $^1\text{H}$  NMR spectra of the purified monoester and the crude reaction mixture confirmed that this product was indeed the dominant one. The separation of the other two products (probably different diesters) from the reaction mixture was not successful, and a mixture of inseparable products was obtained. The substrate scope of the described reaction was expanded with three more monoesters, all of them retaining the substitution in the C-13 position. Although low yields of corresponding marchantin A monoesters were obtained, compared to the base-promoted reaction, a notable selectivity was observed in the lipase-catalyzed reaction, in spite of the excess of vinyl esters employed in both conditions. The regioselective enzymatic esterification could be due to an intramolecular H-bonding within the catechol moiety. Notably, the synthesis of corresponding marchantin A monoesters was accomplished by protecting-group free strategy. Raising the temperature of the lipase-catalyzed reaction to 65 °C and analyzing the crude reaction mixture by NMR spectroscopy showed that the C-13 monoester remained the major product (37% yield), and a peak corresponding to the H-3' of the starting compound was found as well, perhaps due to partial enzyme deactivation. Replicating the reaction conditions outlined in Table 2, in the absence of lipase, led to no product formation.

Table 2.

## 2.2. Structural analysis

Obtained esters were characterized using NMR data. In comparison to marchantin A the main differences in the  $^1\text{H}$  NMR spectra of monoester derivatives (**M1-M4**) were new signals of protons of ester aliphatic chains at  $\delta_{\text{H}} \sim 0.8$  and 1.25-1.35, as well as protons of  $\alpha$ -methylene group (to carbonyl) at  $\delta_{\text{H}} \sim 1.9$  (Table 3, Figs. S8, S12, S16, and S20, Supporting Information). The positions of ester groups (13-OH) in all monoester derivatives were determined according to the shifted signals of H-10 ( $\delta_{\text{H}} \sim 7.3$ ) and H-12 ( $\delta_{\text{H}} \sim 7.0$ ) towards lower fields in comparison to marchantin A for 0.30-0.31 and 0.12 ppm (Tables 3 and S1, Figs. S9, S13, S17, and S21,

Supporting Information), respectively, as it was expected according to the theoretical calculations after substitution of a hydroxyl group with an ester group (Pretch et al., 2008). Additionally, in all monoester derivatives signals of unesterified 3'-OH and 5'-OH groups were noticed (for **ME1** at  $\delta_H$  5.30, for **ME2** at  $\delta_H$  2.89 and 2.95, for **ME3** at  $\delta_H$  5.29, and for **ME4** at  $\delta_H$  5.30) contrary to marchantin A which possess three OH groups ( $\delta_H$  4.86 (13-OH) and 5.32 (3'-OH and 5'-OH, Figs. S2, S8, S12, and S16, Supporting Information). In the  $^{13}C$  NMR spectra of all monoester derivatives novel signals in comparison to marchantin A appeared at  $\delta_C$  ~171 ppm (ester carbonyl C) as well as below 30 ppm (aliphatic ester carbons) (Figs. S10, S11, S14, S15, S18, S19, S22, and S23, Supporting Information). The signals of C-10 and C-12 were shifted towards lower fields for ~6-7 ppm, while the signals of C-13 and C-14 were shifted to the higher fields for ~6 and 4 ppm, respectively (Table S2, Supporting Information).

In comparison to marchantin A the main differences in the  $^1H$  NMR spectra of triesters (**TE1-TE3**) were new signals of protons of ester aliphatic chains at  $\delta_H$  0.8 and 1.25-1.35, as well as protons of  $\alpha$ -methylene group (to carbonyl) at  $\delta_H$  ~1.9, similarly to monoesters (Table 4, Figs. S24, S28, and S32, Supporting Information). The positions of esterified hydroxyl groups (1'-, 6'-, and 13-OH) in all derivatives were determined according to the shifted signals of H-3' ( $\delta_H$  ~5.6), H-5' ( $\delta_H$  ~6.6), H-10 ( $\delta_H$  ~7.3), and H-12 ( $\delta_H$  ~7.0) towards lower fields in comparison to marchantin A (Table 4). The signals of H-10 were shifted in all derivatives for 0.31, signal of H-12 for 0.12, signal of H-5' for 0.10-0.17, while that of H-3' for 0.42-0.44 ppm (Table S1, Supporting Information). Again these changes of chemical shifts caused by the esterification were in accordance with the theoretical calculations (Pretch et al., 2008). In the  $^{13}C$  NMR spectra of all triester derivatives novel signals in comparison to the  $^{13}C$  NMR spectrum of marchantin A appeared at  $\delta_C$  ~170-172 ppm (ester carbonyls C) as well as below 40 ppm (aliphatic ester carbons) (Figs. S26, S27, S30, S31, S34, and S35, Supporting Information). The signals of C-2', C-3', C-4' and C-5' in all triester derivatives were shifted towards lower fields for 5-8 ppm confirming esterifications at C-1' and C-6' (Table S2, Supporting Information). Each position of the shifted carbons at the C-ring possess at least one ester moiety in *ortho* or *para* position, causing higher chemical shifts.

Table 3.

Table 4.

### 2.3. Cytotoxic effects

The cytotoxic effect (anti-proliferative activity) of synthesized compounds was tested on MRC-5 healthy human fibroblast, A549 human lung cancer, and MDA-MB-231 human breast cancer cell lines. The  $IC_{50}$  values were between 9 and 150  $\mu$ M (Table 5). In general, monoesters displayed equal or slightly weaker activity than marchantin A, while cytotoxicity of peresterified products was negligible, presumably due to the blocked catechol group. Cytotoxicity of monoesters against healthy cells was also weaker, to the greater extent than against cancers cells, thus improving the selectivity of **ME3** (marchantin mono hexanoate) against MDA-MB-231 cells in comparison to that of marchantin A by 1.5-fold. From all esters, **ME3** derivative also showed the highest activity against lung cancer cell line A549 (Table 5). An interesting cytotoxic effect of **TE1** was noticed, when compared to **TE2** and **TE3**. Namely, it retained nearly the same activity in all three cell lines, and also a higher activity compared to other two peracylated products. To eliminate partial hydrolysis in the culture medium as the underlying cause of higher activity, **TE1** was subjected to conditions of the anti-proliferative assay. A 100  $\mu$ M solution of **TE1** in DMSO was added to the RPMI mediator and the mixture was kept at 37 °C for 48 h, under constant shaking (100 rpm). The NMR analysis of the resulting mixture showed no traces of hydrolysis products, therefore ruling out the initial hypothesis of partial hydrolysis of **TE1** in the culture medium.

It has been shown previously that marchantin-type bisbibenzyls exhibit anticancer activity. Marchantin A was cytotoxic against A256 breast cancer and against KB (derivative of HeLa) cell lines with  $IC_{50}$  values of 5.5  $\mu$ M and 3.7  $\mu$ M, respectively (Jensen et al., 2012 and Asakawa and Ludwiczuk, 2013). Recently its cytotoxic effects against human melanoma cell line A375 were shown with  $IC_{50}$  values similar to ones obtained in our study (Gawel-Beben, K., 2019).

Table 5.

Despite the facts that neither synthesized derivatives showed significantly higher activity than marchantin A, nor there is a sufficient amount of data to establish firm conclusions, in order to



gain better insight in SAR of investigated compounds, we decided to calculate some of the physically significant molecular descriptors and pharmaceutically relevant properties. For that, we built all molecular structures using Maestro 11.9 from Schrödinger Suite 2019-1 (Maestro, version 11.9, Schrödinger, LLC, New York, NY, 2019.). From the table of properties and descriptors and activities of synthesized compounds and marchantin A (Table S3, Supporting Information), it seems that some of properties are in correlation with activities that compounds showed in biological tests. Most of them are obviously connected with permeability and solubility of investigated compounds. Even though this kind of analysis is based on rather small sample, and no firm conclusions are possible we are rather convinced that those properties are the most probably ones that should be taken into the account, when designing a molecule based on this scaffold, possessing higher activity than compounds tested in this article. The table of calculated properties and descriptors correlated with activities and short description of significant properties has been given in Supporting Information as Table S3.

### 3. Conclusion

In summary, seven previously undescribed marchantin A esters were synthesized. Among these compounds, three peresterified bisbibenzyl products were obtained by chemical synthesis, while lipase-catalyzed regioselective synthesis afforded four monoester derivatives. In addition, the antiproliferative activities of all prepared derivatives of marchantin A were evaluated on MRC5 healthy human lung fibroblast, A549 human lung cancer, and MDA-MB-231 human breast cancer cell lines. It is noteworthy that monoesters displayed higher cytotoxic activities than the corresponding peresterified products, presumably due to the presence of free catechol group. Monohexanoyl ester **ME2** exhibited similar activity against MDA-MB-231 cells and lower cytotoxicity against healthy cells in comparison to marchantin A which makes **ME3** more selective in this regard. This study provides strong evidence that marchantin A is a good structural platform for the further derivatization and finally possible application of its derivatives in the anticancer therapy.

### 4. Experimental section

#### 4.1. General experimental procedures

Dry-flash chromatography was performed on SiO<sub>2</sub> (0.018–0.032 mm). Reaction progress was monitored by thin-layer chromatography (TLC Silica gel 60 F<sub>254</sub> (Merck, Darmstadt)). IR spectra were recorded on a Thermo-Scientific Nicolet 6700 FT-IR Diamond Crystal instrument. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Ultrashield Avance III spectrometer (at 500 and 125 MHz, respectively) using CDCl<sub>3</sub> (unless stated otherwise) as the solvent and tetramethylsilane (TMS) as an internal standard. Chemical shifts are expressed in parts per million (ppm) on the (δ) scale. Chemical shifts were calibrated relative to those of the solvent. Optical rotations were measured on a Rudolph Research Analytical Autopol IV automatic polarimeter with methanol as solvent, and the compound concentration used was in the range of 0.8–4.0 mg/mL. UV spectra were recorded on a GBC Cintra UV/vis spectrometer with methanol as solvent. HRMS spectra were data were obtained on an Agilent 5210 time-of-flight LC/MS system equipped with an ESI interface (ESI-TOF/MS). The solvent was methanol, and the mobile phase was 0.2% HCOOH<sub>(aq)</sub>/CH<sub>3</sub>CN, 1:1, 0.2 mL/min. The ESI was operated in a negative and a positive mode, and nitrogen was used as the drying gas (12 L/min) and nebulizing gas at 350 °C (45 psi). The OCT RF voltage was set to 250 V, and the capillary voltage was set to 4.0 kV. The voltages applied to the fragmentor and skimmer were 140 and 60 V, respectively. Scanning was performed from *m/z* 100 to 1500. All compounds used for biological assays are of ≥95% purity based on HPLC. The HPLC purity of Marchantin A, **ME1-ME4** and **TE1-TE3** was determined by Agilent 1200 HPLC system fitted with Quat Pump (G1311B), Injector (G1329B) 1260 ALS, TCC 1260 (G1316A) and Detector 1260 DAD VL+ (G1315C). Prior to purity determination and *in vitro* assays, the tested compounds were purified by semi-preparative HPLC. For this purpose a C18 reversed-phase column (Zorbax ODS Semi-Preparative 5 μm 9.4 × 250 mm) was used. Gradient elution was performed, using 0.2% HCO<sub>2</sub>H<sub>(aq)</sub> (A)/CH<sub>3</sub>CN (B): 0-12 min 70% A → 50% A, 12-14 min 50% A → 0% A, 14-19 min 0% A. The flow rate was set to 4 mL/min. The purity of reported compounds was tested with two HPLC methods: Method A. The LC system was fitted with a C18 reversed-phase column (Poroshell 120 SB-C18, 2.7 μm, 4.6 × 50 mm) and gradient elution was performed using H<sub>2</sub>O (A) and CH<sub>3</sub>CN (B) as solvents, in the following manner: 0-1 min 95% A, 1-6 min 95% A → 5% A, 6-22 min 5% A, 22-25 min 5% A → 95% A. The flow rate was set to 0.7 mL/min. Method B is identical to Method A, apart from MeOH being used as solvent B.

#### 4.2. Reagents and chemicals

Marchantin A was isolated from *Marchantia polymorpha* by a previously reported procedure [Asakawa et al, 1983]. Novozym<sup>®</sup> 40086 was a gift from Novozymes A/S (Bagsværd, Denmark). Unless stated otherwise, solvents and other reagents were obtained from commercial sources and used without further purification.

#### 4.3. Computational methods

All molecular structures were built using Maestro 11.9 from Schrödinger Suite 2019-1 (Maestro, version 11.9, Schrödinger, LLC, New York, NY, 2019.). All structures were submitted to Conformational search from the MacroModel module (MacroModel version 12.3, Schrödinger, LLC, New York, NY, 2019.). The OPLS\_2005 force field, with water as the solvent were used. For the conformational search method we used mixed MCM/low-mode [Kolossváry and Guida, 1999], were the set parameters. Conformations were minimized using the Polak–Ribiere conjugate gradient method [Polak and Ribiere, 1969], with 25000 maximum iterations or until a 0.05 convergence threshold was obtained. Duplicates were removed and all structures within energy window of 10.5 kJ/mol were saved. Best conformers were selected and calculation of physically significant molecular descriptors and pharmaceutically relevant properties was performed using QikProp (QikProp, version 5.9, Schrödinger, LLC, New York, NY, 2019.).

#### 4.4. General procedure for the peracylation of marchantin A

A previously reported procedure for the *O*-acylation of phenols was modified and employed in this work (Zhou and Chen, 2018). A reaction vial was charged with marchantin A (35 mM), Na<sub>2</sub>CO<sub>3</sub> (4.8 mg, 45 mM), and MeCN (1.3 mL). The appropriate vinyl-ester was added dropwise (final concentration 420 mM) to the reaction mixture under constant magnetic stirring. The vial was crimped and heated at 120 °C for 24 h. The reaction mixture was filtered, washed with MeCN (5 mL) and the solvents were removed under reduced pressure. The crude product was dried under high-vacuum, and NMR analysis confirmed that no further purification was necessary. All products **TE1**, **TE2**, and **TE3** were obtained in quantities of 26.4, 28.0, and 28.1 mg, respectively and their HPLC purities were over 95%.

#### 4.5. General procedure for the lipase-catalyzed acylation of marchantin A

A reaction vial was charged with marchantin A (23 mM), Novozym<sup>®</sup> 40086 (1.6 g/mmol of substrate), and *i*-Pr<sub>2</sub>O (44.4 mL/mmol of substrate). The appropriate vinyl-ester was added dropwise (final concentration 460 mM) to the reaction mixture under constant magnetic stirring. The vial was crimped and heated at 45 °C for 24 h. The enzyme was separated from the reaction mixture by filtration and washed with CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The filtrate was collected and concentrated under reduced pressure. The crude products were purified by Dry-flash chromatography (SiO<sub>2</sub>, Hex/EtOAc 7:3 v/v) or preparative Thin-layer chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH 97:3 v/v).

All products **ME1**, **ME2**, **ME3**, and **ME4** were obtained in quantities of 8.1, 10.1, 32.0, and 1.5 mg, respectively and their HPLC purities were over 95%.

#### 4.6. *In vitro* antiproliferative assays

For the determination of cytotoxicity of synthesized compounds and Marchantin A, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay was used. The compounds were tested against MRC-5, A549 lung cancer and MDA-MB-231 breast cancer cell lines. The cells were incubated for 24 h in an RPMI-1640 medium with 10<sup>4</sup> colonies per well. The assay was done in 96 well flat-bottom microtiter plates (Sarstedt, Germany). After incubation, cells were treated with marchantin A and corresponding esters (dissolved in DMSO ((100 mM), filtered through a 0.2 μm filter, EMD Millipore, Billerica, USA) with final concentrations ranging from 0.5 – 250 μM. DMSO was used as a negative control. The cells were treated with the mentioned compounds for 48 h, and MTT (Sigma Aldrich, St. Louis, MO, USA) dissolved in RPMI medium (0.5 mg/mL) was added to each well subsequently. After an incubation time of 30 min at 37 °C, the medium was carefully removed by pipetting and DMSO (50 μL, 100%) was added to the adherent cells with formazan crystals in order to dissolve the formazan crystals. The absorbance of resulting solutions was measured with a *Tecan Infinite 200 pro multiplate reader* at a wavelength of 540 nm. The results were presented relative to the DMSO negative control. The cytotoxicity was presented as the IC<sub>50</sub> value, the compound concentration value causing survival of 50% of the cells.

#### *1',6',13-n-tripropanoylmarchantin A (TE1)*

Viscous colorless oil;  $[\alpha]_{\text{D}}^{22} +5.0$  ( $c$  1.0, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 274 (3.23), 238 (3.99), 229 (4.19) nm; IR (ATR)  $\nu_{\text{max}}$ : 2983, 2941, 1769, 1593, 1505, 1461, 1351, 1318, 1268, 1213, 1187, 1138, 1079, 1040, 907, 859, 781, 736, 697; ESI-HRMS  $m/z$  567.2741  $[\text{M}+\text{H}]^+$  (calcd. for  $\text{C}_{36}\text{H}_{39}\text{O}_6$  567.2747);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) 7.34 (dd,  $J = 8.0, 1.5$  Hz, 1H), 7.20 (t,  $J = 8.0$  Hz, 1H), 6.99 (dd,  $J = 8.0, 1.5$  Hz, 1H), 6.93-6.97 (m, 3H), 6.64 (d,  $J = 1.5$  Hz, 1H), 6.59 (d,  $J = 8.5$  Hz, 2H), 6.50 (dd,  $J = 8.0, 1.5$  Hz, 1H), 6.43 (brs, 1H), 6.39 (brd,  $J = 8.0$  Hz, 1H), 5.58 (d,  $J = 1.5$  Hz, 1H), 3.00-3.10 (m, 4H), 2.86-2.90 (m, 2H), 2.70-2.77 (m, 2H), 2.52-2.56 (m, 4H), 1.91 (q,  $J = 7.5$  Hz, 2H), 1.27 (t,  $J = 7.5$  Hz, 3H), 1.22 ( $J = 7.5$  Hz, 3H), 0.82 (t,  $J = 7.5$  Hz, 3H);  $^{13}\text{C}$  NMR (125 Hz,  $\text{CDCl}_3$ ) 171.9, 171.6, 171.4, 157.4, 152.9, 151.5, 143.9, 143.1, 142.5, 141.5, 138.6, 138.4, 136.6, 129.6, 128.6, 128.1, 124.7, 122.3, 121.6, 121.3, 115.9, 115.1, 114.0, 113.1, 36.1, 34.9, 34.3, 30.0, 27.5, 27.2, 27.0, 9.3, 9.2, 8.4

*1',6',13-n-tributanoylmarchantin A (TE2)*

Viscous colorless oil;  $[\alpha]_{\text{D}}^{22} +6.0$  ( $c$  0.8, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 274 (3.43), 238 (4.10), 231 (4.33) nm; IR (ATR)  $\nu_{\text{max}}$ : 3510, 3033, 2966, 2934, 2875, 1767, 1594, 1505, 1463, 1349, 1311, 1268, 1244, 1213, 1183, 1142, 1097, 1038, 915, 850, 777, 733, 695; ESI-HRMS  $m/z$  651.2954  $[\text{M}+\text{H}]^+$  (calcd. for  $\text{C}_{40}\text{H}_{43}\text{O}_8$  651.2958);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) 7.33 (dd,  $J = 8.0, 1.5$  Hz, 1H), 7.21 (t,  $J = 8.0$  Hz, 1H), 6.99 (dd,  $J = 8.0, 1.5$  Hz, 1H), 6.93-6.97 (m, 3H), 6.65 (d,  $J = 1.5$  Hz, 1H), 6.59 (d,  $J = 8.5$  Hz, 2H), 6.50 (dd,  $J = 8.0, 1.5$  Hz, 1H), 6.43 (brs, 1H), 6.39 (brd,  $J = 8.0$  Hz, 1H), 5.58 (d,  $J = 1.5$  Hz, 1H), 3.01-3.10 (m, 4H), 2.87-2.91 (m, 2H), 2.73-2.77 (m, 2H), 2.50-2.54 (m, 4H), 1.88 (t,  $J = 7.5$  Hz, 2H), 1.76 (sext, 2H), 1.74 (sext, 2H), 1.33 (sext, 2H), 1.04 (t,  $J = 7.5$  Hz, 3H), 0.97 (t,  $J = 7.5$  Hz, 3H), 0.76 (t,  $J = 7.5$  Hz, 3H);  $^{13}\text{C}$  NMR (125 Hz,  $\text{CDCl}_3$ ) 171.1, 170.8, 170.6, 157.3, 152.8, 151.5, 143.9, 143.1, 142.5, 141.5, 138.6, 138.4, 137.7, 130.0, 129.6, 128.6, 128.1, 124.7, 122.3, 121.6, 121.3, 115.9, 115.2, 114.0, 113.0, 36.1, 35.9, 35.6, 35.4, 34.9, 34.3, 30.1, 18.5, 18.4, 17.7, 13.6, 13.5, 13.4.

*1',6',13-n-trihexanoylmarchantin A (TE3)*

Viscous colorless oil;  $[\alpha]_{\text{D}}^{22} +5.0$  ( $c$  1.0, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 271 (3.34), 238 (4.05), 233 (4.01) nm; IR (ATR)  $\nu_{\text{max}}$ : 3472, 3033, 2957, 2931, 2864, 1768, 1593, 1505, 1463,

1348, 1315, 1268, 1212, 1140, 1098, 1041, 912, 851, 776, 733, 695; ESI-HRMS  $m/z$  735.3892 [M+H]<sup>+</sup> (calcd. for C<sub>46</sub>H<sub>55</sub>O<sub>8</sub> 735.3897); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) 7.33 (dd,  $J$  = 8.0, 1.5 Hz, 1H), 7.21 (t,  $J$  = 8.0 Hz, 1H), 6.99 (dd,  $J$  = 8.0, 1.5 Hz, 1H), 6.93-6.97 (m, 3H), 6.64 (d,  $J$  = 1.5 Hz, 1H), 6.59 (d,  $J$  = 8.5 Hz, 2H), 6.48 (dd,  $J$  = 8.0, 1.5 Hz, 1H), 6.43 (brs, 1H), 6.37 (brd,  $J$  = 8.0 Hz, 1H), 5.56 (d,  $J$  = 1.5 Hz, 1H), 3.02-3.09 (m, 4H), 2.85-2.89 (m, 2H), 2.73-2.78 (m, 2H), 2.48-2.56 (m, 4H), 1.89 (t,  $J$  = 7.5 Hz, 2H), 1.69-1.79 (m, 4H), 1.24-1.41 (m, 10H), 1.06-1.20 (m, 4H), 0.94 (t,  $J$  = 7.5 Hz, 3H), 0.78-0.87 (m, 6H); <sup>13</sup>C NMR (125 Hz, CDCl<sub>3</sub>) 171.2, 171.0, 170.8, 157.4, 152.8, 151.5, 143.9, 143.1, 142.6, 141.4, 138.6, 138.4, 136.7, 129.6, 128.5, 128.1, 124.7, 122.4, 121.6, 121.3, 115.9, 115.1, 114.0, 113.0, 36.1, 35.0, 34.3, 34.0, 33.7, 33.6, 31.2, 31.1, 31.0, 29.9, 24.7, 24.6, 23.8, 22.3, 22.2, 22.1, 13.9, 13.8, 13.7.

### *13-n-propanoylmarchantin A (ME1)*

Viscous colorless oil;  $[\alpha]_D^{22}$  +4.5 ( $c$  0.9, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ): 274 (3.26), 238 (3.94), 231 (4.17) nm; IR (ATR)  $\nu_{\max}$ : 3443, 3033, 2922, 2854, 1763, 1604, 1508, 1461, 1353, 1268, 1213, 1140, 1077, 1027, 993, 961, 906, 847, 786, 735, 697, 458; HRESIMS  $m/z$  495.1828 [M - H]<sup>-</sup> (calcd. for C<sub>31</sub>H<sub>27</sub>O<sub>6</sub> 495.1808); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) 7.33 (dd,  $J$  = 8.0, 1.5 Hz, 1H), 7.20 (t,  $J$  = 8.0 Hz, 1H), 6.98 (m, 3H), 6.92 (t,  $J$  = 7.5 Hz, 1H), 6.59 (d,  $J$  = 8.5 Hz, 2H), 6.48 (dd,  $J$  = 8.0, 1.5 Hz, 2H), 6.46 (d,  $J$  = 1.5 Hz, 1H), 6.38 (brd,  $J$  = 7.5 Hz, 1H), 5.26-5.31 (m, 2H), 5.21 (d,  $J$  = 1.6 Hz, 1H), 3.02-3.10 (m, 4H), 2.72-2.82 (m, 4H), 1.90 (q,  $J$  = 7.5 Hz, 2H), 0.82 (t,  $J$  = 7.5 Hz, 3H); <sup>13</sup>C NMR (125 Hz, CDCl<sub>3</sub>)  $\delta$ : 171.6, 157.3, 152.9, 146.1, 144.1, 144.0, 142.4, 142.2, 138.4, 136.5, 132.5, 130.6, 129.7, 128.3, 128.1, 124.6, 122.5, 121.7, 121.1, 115.3, 112.8, 109.3, 107.8, 36.1, 35.4, 34.3, 30.1, 27.0, 8.4.

### *13-n-butanoylmarchantin A (ME2)*

Viscous colorless oil;  $[\alpha]_D^{22}$  + 1.0 ( $c$  4.0, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ): 282 (3.43), 272 (3.55), 240 (4.01); IR (ATR)  $\nu_{\max}$ : 3421, 2929, 2858, 2155, 1763, 1662, 1604, 1509, 1462, 1342, 1268, 1246, 1215, 1141, 1099, 1031, 850, 772; ESI-HRMS  $m/z$  509.1977 [M - H]<sup>-</sup> (calcd. for C<sub>32</sub>H<sub>29</sub>O<sub>6</sub> 509.1964); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) 7.33 (dd,  $J$  = 8.0, 1.5 Hz, 1H), 7.20 (t,  $J$  = 8.0 Hz, 1H), 6.98 (m, 3H), 6.92 (t,  $J$  = 7.5 Hz, 1H), 6.59 (d,  $J$  = 8.5 Hz, 2H), 6.43-6.48 (m, 3H), 6.38

(brd,  $J=7.5$  Hz, 1H), 5.26-5.31 (m, 2H), 5.21 (d,  $J=1.5$  Hz, 1H), 3.03-3.09 (m, 4H), 2.71-2.81 (m, 4H), 1.87 (t,  $J=7.5$  Hz, 2H), 1.30-1.33 (m, 2H), 0.76 (t,  $J=7.5$  Hz, 3H);  $^{13}\text{C}$  NMR (125 Hz,  $\text{CDCl}_3$ ) 170.9, 157.3, 153.0, 146.2, 144.2, 144.0, 142.5, 142.3, 138.5, 136.6, 132.5, 130.7, 129.6, 128.3, 128.1, 124.7, 122.5, 121.6, 121.1, 115.4, 112.8, 109.3, 107.9, 36.1, 35.5, 35.4, 34.3, 30.1, 17.9, 13.5.

### *13-n-hexanoylmarchantin A* (ME3)

Viscous colorless oil;  $[\alpha]_{\text{D}}^{22} +4.0$  (c 1.0, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 280 (3.37), 274 (3.48), 238 (4.16), 227 (3.98); IR (ATR)  $\nu_{\text{max}}$ : 3436, 3033, 2930, 2850, 1763, 1605, 1508, 1462, 1343, 1268, 1214, 1142, 1101, 1028, 995, 961, 910, 848, 774, 730, 694; ESI-HRMS  $m/z$  539.2428  $[\text{M}+\text{H}]^+$  (calcd. for  $\text{C}_{34}\text{H}_{35}\text{O}_6$  539.2434);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) 7.32 (brd,  $J=8.0$  Hz, 1H), 7.20 (t,  $J=8.0$  Hz, 1H), 6.95-6.98 (m, 3F), 6.91 (t,  $J=7.5$  Hz, 1H), 6.59 (d,  $J=8.5$  Hz, 2H), 6.43-6.48 (m, 3H), 6.36 (brd,  $J=7.5$  Hz, 1F), 5.26-5.31 (m, 2H), 5.18 (d,  $J=1.5$  Hz, 1H), 3.02-3.09 (m, 4H), 2.70-2.80 (m, 4H), 1.89 (t,  $J=7.5$  Hz, 2H), 1.09-1.34 (m, 6H), 0.81 (t,  $J=7.5$  Hz, 3H);  $^{13}\text{C}$  NMR (125 Hz,  $\text{CDCl}_3$ ) 171.0, 157.3, 152.9, 146.1, 144.1, 144.0, 142.6, 142.2, 138.5, 136.6, 132.5, 130.6, 129.6, 128.3, 128.1, 124.7, 122.5, 121.6, 121.2, 115.4, 112.7, 109.3, 107.8, 36.1, 35.5, 34.4, 33.6, 31.1, 30.1, 23.8, 22.1, 13.8.

### *13-n-octanoylmarchantin A* (ME4)

Viscous colorless oil;  $[\alpha]_{\text{D}}^{22} +3.0$  (c 1.0, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 282 (3.46), 274 (3.64), 238 (4.13), 233 (4.15); IR (ATR)  $\nu_{\text{max}}$ : 3433, 3033, 2927, 2856, 1764, 1606, 1506, 1463, 1343, 1246, 1215, 1207, 1141, 1103, 1029, 960, 909, 847, 770, 730, 694; ESI-HRMS  $m/z$  567.2741  $[\text{M}+\text{H}]^+$  (calcd. for  $\text{C}_{36}\text{H}_{39}\text{O}_6$  567.2747);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) 7.33 (dd,  $J=8.0$ , 1.5 Hz, 1H), 7.21 (t,  $J=8.0$  Hz, 1H), 6.99 (m, 3H), 6.92 (t,  $J=7.5$  Hz, 1H), 6.59 (d,  $J=8.5$  Hz, 2H), 6.45-6.48 (m, 3H), 6.36 (brd,  $J=7.5$  Hz, 1H), 5.30 (s, 2H), 5.18 (d,  $J=1.5$  Hz, 1H), 3.03-3.09 (m, 4H), 2.71-2.81 (m, 4H), 1.89 (t,  $J=7.5$  Hz, 2H), 1.09-1.28 (m, 10H), 0.86 (t,  $J=7.5$  Hz, 3H);  $^{13}\text{C}$  NMR (125 Hz,  $\text{CDCl}_3$ ) 171.0, 157.3, 152.9, 146.2, 144.1, 144.0, 142.6, 142.2, 138.5, 136.6, 132.5, 130.6, 129.7, 128.3, 128.1, 124.7, 122.5, 121.6, 121.2, 115.4, 112.8, 109.3, 107.8, 36.1,

35.5, 34.4, 33.7, 31.5, 28.9, 28.8, 24.2, 22.6, 14.0.

### **Acknowledgements**

This study was financially supported by the Ministry of Education, Science and Technological Development of Republic of Serbia, Projects Nos. 172053, 172008, and 173048.

### **Declaration of Competing Interest**


The authors declare no conflict of interest.

Journal Pre-proof



**Table 1**


The peracylation of marchantin A.



Entry	Compound	R	Isolated yield (%)
1	<b>TE1</b>	-CH <sub>2</sub> CH <sub>3</sub>	96
2	<b>TE2</b>	-(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	96
3	<b>TE3</b>	-(CH <sub>2</sub> ) <sub>4</sub> CH <sub>3</sub>	85

**Table 2**

The lipase-catalyzed monoacylation of marchantin A.



Entry	Compound	R	Isolated yield (%)
1	<b>ME1</b>	-CH <sub>2</sub> CH <sub>3</sub>	36
2	<b>ME2</b>	-(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	43
3	<b>ME3</b>	-(CH <sub>2</sub> ) <sub>4</sub> CH <sub>3</sub>	52
4	<b>ME4</b>	-(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	24

**Table 3**Comparison of  $^1\text{H}$ NMR data of marchantin A and its monoester derivatives ME1-ME4.

Position	MA	ME1	ME2	ME3	ME4
	$\delta_{\text{H}}$	$\delta_{\text{H}}$	$\delta_{\text{H}}$	$\delta_{\text{H}}$	$\delta_{\text{H}}$
1	-	-	-	-	-
2,6	6.58 d (8.5)	6.59 d (8.5)	6.59 d (8.5)	6.59 d (8.5)	6.59 d (8.0)
3,5	6.93 d (8.5)	6.98 d (8.5) <sup>a</sup>	6.97 d (8.5) <sup>a</sup>	6.97 d (8.5) <sup>a</sup>	6.97 d (8.0) <sup>a</sup>
4	-	-	-	-	-
7,8	2.96-3.01 m	3.02-3.10 m	3.03-3.09 m	3.02-3.09 m	3.03-3.09 m
9	-	-	-	-	-
10	7.02 dd (8.0; 1.5)	7.33 dd (8.0; 1.5)	7.33 dd (8.0; 1.5)	7.32 brd (7.5)	7.33 dd (8.0; 1.5)
11	7.15 t (8.0)	7.20 t (8.0)	7.20 t (8.0)	7.20 t (8.0)	7.21 t (8.0)
12	6.87 dd (8.0; 1.5)	6.98 dd (8.0; 1.5) <sup>a</sup>	6.98 dd (8.0; 1.5) <sup>a</sup>	6.95-7.00 m <sup>a</sup>	6.99 m <sup>a</sup>
13	-	-	-	-	-
14	-	-	-	-	-
1'	-	-	-	-	-
2'	-	-	-	-	-
3'	5.13 d (2.0)	5.21 d (1.5)	5.21 d (1.5)	5.19 brs	5.18 d (1.5)
4'	-	-	-	-	-
5'	6.47 d (2.0)	6.46 d (1.5) <sup>b</sup>	6.46 brs <sup>b</sup>	6.45 brs <sup>b</sup>	6.46 brs <sup>b</sup>
6'	-	-	-	-	-
7',8'	2.72-2.78 m	2.70-2.82 m	2.71-2.81 m	2.70-2.80 m	2.71-2.81 m
9'	-	-	-	-	-
10'	6.57 t (8.0)	6.44 m <sup>b</sup>	6.43 m <sup>b</sup>	6.43-6.48 m <sup>b</sup>	6.45-6.48 m <sup>b</sup>
11'	-	-	-	-	-
12'	6.55 dd	6.48 dd	6.43 m <sup>b</sup>	6.43-6.48 m <sup>b</sup>	6.45-6.48 m <sup>b</sup>

	(7.5; 1.5)	(8.0; 1.5) <sup>b</sup>			
13'	6.98 t (7.5)	6.92 t (7.5)	6.92 t (7.5)	6.91 t (7.5)	6.92 t (7.5)
14'	6.41 brd (7.5)	6.38 brd (7.5)	6.38 brd (7.5)	6.37 brd (7.5)	6.36 brd (7.5)
$\alpha$ -CH <sub>2</sub>	-	1.90 q (7.5)	1.87 t (7.5)	1.89 t (7.5)	1.89 t (7.5)
(CH <sub>2</sub> ) <sub>n</sub>	-	-	1.30-1.33 m	1.09-1.34 m	1.09-1.28 m
CH <sub>3</sub>	-	0.82 t (7.5)	0.76 t (7.5)	0.81 t (7.5)	0.86 t (7.5)

<sup>a,b</sup> - signals overlapped;  $\alpha$ -CH<sub>2</sub> - methylene group next to ester moiety; (CH<sub>2</sub>)<sub>n</sub> - other methylene groups of ester

**Table 4**

Comparison of <sup>1</sup>H NMR data of marchantin A and its triester derivatives TE1-TE3.

Position	MA	TE1	TE2	TE3
	$\delta_H$	$\delta_H$	$\delta_H$	$\delta_H$
1	-	-	-	-
2,6	6.58 d (8.5)	6.59 d (8.5)	6.59 d (8.5)	6.59 d (8.5)
3,5	6.93 d (8.5)	6.95 d (8.5) <sup>a</sup>	6.94 d (8.5) <sup>a</sup>	6.95 d (8.5) <sup>a</sup>
4	-	-	-	-
7,8	2.96-3.01 m	3.00-3.10 m	3.01-3.10 m	3.02-3.09 m
9	-	-	-	-
10	7.02 dd (8.0; 1.5)	7.34 dd (8.0; 1.5)	7.33 dd (8.0; 1.5)	7.33 dd (8.0; 1.5)
11	7.15 t (8.0)	7.21 t (8.0)	7.20 t (8.0)	7.21 t (8.0)
12	6.87 dd (8.0; 1.5)	6.99 dd (8.0; 1.5)	6.99 dd (8.0; 1.5)	6.99 dd (8.0; 1.5)
13	-	-	-	-
14	-	-	-	-
1'	-	-	-	-
2'	-	-	-	-
3'	5.13 d (2.0)	5.58 d (1.5)	5.58 d (1.5)	5.56 d (1.5)
4'	-	-	-	-

5'	6.47 d (2.0)	6.65 d (1.5)	6.64 d (1.5)	6.64 d (1.5)
6'	-	-	-	-
7',8'	2.72-2.78 m	2.70-2.90 m	2.73-2.91 m	2.73-2.89 m
9'	-	-	-	-
10'	6.57 t (8.0)	6.43 brs	6.43 brs	6.44 brs
11'	-	-	-	-
12'	6.55 dd (8.0; 1.5)	6.50 dd (8.0; 1.5)	6.50 d (8.0; 1.5)	6.48 d (8.0; 2.0)
13'	6.98 t (8.0)	6.95 t (8.0) <sup>a</sup>	6.95 m <sup>a</sup>	6.95m <sup>a</sup>
14'	6.41 brd (8.0)	6.39 brd (8.0)	6.39 brd (8.0)	6.37 brd (8.0)
		1.91 q (7.5)	1.88 t (7.5)	1.89 t (7.5)
3 $\alpha$ -CH <sub>2</sub>	-	2.56 q (7.5)	2.52 t (7.5)	2.52 t (7.5)
		2.56 q (7.5)	2.53 t (7.5)	2.53 t (7.5)
			1.73 sext	
(CH <sub>2</sub> ) <sub>n</sub>	-	-	1.74 sext	1.07-1.42 m
			1.76 sext	1.69-1.79 m
		0.82 t (7.5)	0.76 t (7.5)	0.81 t (7.5)
3xCH <sub>3</sub>	-	1.27 t (7.5)	0.97 t (7.5)	0.83 t (7.5)
		1.27 t (7.5)	1.04 t (7.0)	0.94 t (7.5)

<sup>a</sup> - signals overlapped;  $\alpha$ -CH<sub>2</sub> - methylene group next to ester moiety; (CH<sub>2</sub>)<sub>n</sub> - other methylene groups of ester

**Table 5**

*In-vitro* cytotoxicity of marchantin A and synthesized derivatives against three cell lines (MRC5, A549 and MDA-MB-231) following 48 h incubation time.

Compound	Cytotoxicity, IC <sub>50</sub> (μM)		
	MRC5 <sup>a</sup>	A549 <sup>b</sup>	MDA-MB-231 <sup>c</sup>
<b>MA</b>	28±2 <sup>d</sup>	12±1	9±1
<b>ME1</b>	45±3	25±2	13±2
<b>TE1</b>	45±5	40±4	40±6
<b>ME2</b>	40±2	25±1	18±2
<b>TE2</b>	80±7	90±5	40±6
<b>ME3</b>	40±1	18±2	9±1
<b>TE3</b>	150±5	90±3	65±4
<b>ME4</b>	42±2	20±4	12±2

<sup>a</sup> healthy human fibroblast

<sup>b</sup> human lung cancer cell line

<sup>c</sup> human breast cancer cell line

<sup>d</sup> IC<sub>50</sub> values are the mean of three independent repetitions ± SD

## References

- Abdelmoez, W., Mustafa, A., 2014. Oleochemical Industry Future through Biotechnology. *J. Oleo Sci.* 63, 545–554. <https://doi.org/10.5650/jos.ess14022>
- Asakawa, Y., 1982. Chemical constituents of Hepaticae. in: *Progress in the chemistry of organic natural products.* (Herz, W., Grisebach, H. and Kirby, G. W. eds) Vol 42. p. 1-285. Springer, Wien.
- Asakawa, Y., 1990. Terpenoids and aromatic compounds with pharmaceutical activity from bryophytes. in: *Bryophytes their chemistry and chemical taxonomy* (Zinsmeister, H. D. and Mues, R. eds.) p. 369-410. Oxford University Press, Oxford.
- Asakawa, Y., 1995. Chemical constituents of bryophytes. In: *Progress in the chemistry of organic natural products* (Herz, W., Kirby, W. G., Moore, F. E., Steglich, W. and Tamm, Ch., eds) Vol. 65, p.1-618. Springer, Wein.
- Asakawa, Y., Ludwiczuk, A., 2018. Chemical constituents of bryophytes: structures and biological activity. *J. Nat. Prod.* 81, 641-660.
- Asakawa, Y., Ludwiczuk, A., Nagashima, F., 2013. Chemical constituents of bryophytes: Bio- and chemical diversity, biological activity, and chemosystematics. In: *Progress in the chemistry of organic natural products* (Kinghorn D, A., Heinz, F., Kobayashi, J. eds). Vol. 95, pp. 1-796. Springer, Vienna & New York.
- Asakawa, Y., Toyota, M., Matsuda, R., Takikawa, K., Takemoto, T., 1983. Distribution of novel cyclic bisbibenzyls in *Marchantia* and *Riccardia* species. *Phytochemistry* 22, 1413. [https://doi.org/10.1016/S0031-9422\(00\)84025-X](https://doi.org/10.1016/S0031-9422(00)84025-X)
- Asakawa, Y., Ludwiczuk, A., 2013. Bryophytes: liverworts, mosses, and hornworts: extraction and isolation procedures. In: *Roessner, U., Dias, D.A. (Eds.), Metabolomics Tools for Natural Product Discovery: Methods and Protocols*, vol. 1055. Humana Press, New York, USA, pp. 1–20.
- Candiracci, M., Madrona, A., Espartero, J.L., Zappia, G., Piatti, E., 2016. Lipophilic hydroxytyrosol esters significantly improve the oxidative state of human red blood cells. *J. Funct. Foods* 23, 339–347. <https://doi.org/10.1016/J.JFF.2016.02.049>
- Carey, J.S., McCann, E., 2019. Lipase-catalyzed regioselective ester hydrolysis as a key step in an alternative synthesis of a buprenorphine pro-drug. *Org. Process Res. Dev.* 23, 771–774. <https://doi.org/10.1021/acs.oprd.9b00026>


- de Miranda, A.S., 2015. Lipases: Valuable catalysts for dynamic kinetic resolutions. *Biotechnol. Adv.* 33, 372–393. <https://doi.org/10.1016/J.BIOTECHADV.2015.02.015>
- Facchetti, I., Grandi, M., Cucchi, P., Geroni, C., Penco, S., Vigevani, A., 1991. Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. *Anticancer. Drug Des.* 6, 385–97.
- Ferreira-Dias, S., Sandoval, G., Plou, F., Valero, F., 2013. The potential use of lipases in the production of fatty acid derivatives for the food and nutraceutical industries. *Electron. J. Biotechnol.* 16, 12–12. <https://doi.org/10.2225/vol16-issue3-fulltext-5>
- Gaweł-Bęben, K., Osika, P., Asakawa, Y., Antosiewicz, B., Główniak, K., Ludwiczuk, A., 2019. Evaluation of anti-melanoma and tyrosinase inhibitory properties of marchantin A, a natural macrocyclic bisbibenzyl isolated from *Marchantia* species. *J. phytochem. Lett.* 31, 192–195. <https://doi.org/10.1016/J.PHYTOL.2019.04.008>
- Hama, S., Noda, H., 2018. How lipase technology contributes to evolution of biodiesel production using multiple feedstocks. *Curr. Opin. Biotechnol.* 50, 57–64. <https://doi.org/10.1016/J.COPBIO.2017.11.001>
- Harinantenaina, L., Quang, D.N., Takeshi, M., Hashimoto, T., Kohchi, Chie., Soma, G.-I., Asakawa, Y., 2005. Bis(bibenzyls) From Liverworts Inhibit Lipopolysaccharide-Induced Inducible NOS in RAW 264.7 cells: A Study of Structure–Activity Relationships and Molecular Mechanism. <https://doi.org/10.1021/NP0502589>
- He, X., Sun, Y., Zhu, R.-L., 2013. The Oil Bodies of Liverworts: Unique and Important Organelles in Land Plants. *CRC. Crit. Rev. Plant Sci.* 32, 293–302. <https://doi.org/10.1080/07352689.2013.765765>
- Huang, W.-J., Wu, C.-L., Lin, C.-W., Chi, L.-L., Chen, P.-Y., Chiu, C.-J., Huang, C.-Y., Chen, C.-N., 2010. Marchantin A, a cyclic bis(bibenzyl ether), isolated from the liverwort *Marchantia emarginata* subsp. *tosana* induces apoptosis in human MCF-7 breast cancer cells. *Cancer Lett.* 291, 108–119. <https://doi.org/10.1016/J.CANLET.2009.10.006>
- Iwai, Y., Murakami, K., Gomi, Y., Hashimoto, T., Asakawa, Y., Okuno, Y., Ishikawa, T., Hatakeyama, D., Echigo, N., Kuzuhara, T., 2011. Anti-Influenza Activity of Marchantins, Macrocyclic Bisbibenzyls Contained in Liverworts. *PLoS One* 6, e19825. <https://doi.org/10.1371/journal.pone.0019825>
- Jensen, J., Omarsdottir, S., Thorsteinsdottir, J., Ogmundsdottir, H., Olafsdottir, E., 2012.



- Synergistic Cytotoxic Effect of the Microtubule Inhibitor Marchantin A from *Marchantia polymorpha* and the Aurora Kinase Inhibitor MLN8237 on Breast Cancer Cells *In Vitro*. *Planta Med.* 78, 448–454. <https://doi.org/10.1055/s-0031-1298230>
- Jensen, S., Omarsdottir, S., Bwalya, A.G., Nielsen, M.A., Tasdemir, D., Olafsdottir, E.S., 2012. Marchantin A, a macrocyclic bisbibenzyl ether, isolated from the liverwort *Marchantia polymorpha*, inhibits protozoal growth *in vitro*. *Phytomedicine* 19, 1191–1195. <https://doi.org/10.1016/J.PHYMED.2012.07.011>
- Jurado, E., García-Román, M., Luzón, G., Altmajer-Vaz, D., Jiménez-Pérez, J.L., 2011. Optimization of Lipase Performance in Detergent Formulations for Hard Surfaces. *Ind. Eng. Chem. Res.* 50, 11502–11510. <https://doi.org/10.1021/ie201186z>
- Kámory, E., Keserü, G.M., Papp, B., 1995. Isolation and antibacterial activity of marchantin A, a cyclic bis(bibenzyl) constituent of Hungarian *Marchantia polymorpha*. *Planta Med.* 61, 387–8.
- Kosenkova, Y.S., Polovinka, M.P., Komarova, N.I., Korchagina, D. V., Kurochkina, N.Y., Cheremushkina, V.A., Salakhutdinov, M.F., 2007. Riccardin C, a bisbibenzyl compound from *Primula macrocalyx*. *Chem. Nat. Compd.* 43, 712–713. <https://doi.org/10.1007/s10600-007-0241-8>
- Kolossváry, I., Guida, W.C., 1999. Low-mode conformational search elucidated: application to C39H80 and flexible docking of 9-deazaguanine inhibitors into PNP, *J. Comput. Chem.*, 20, 1671-1684. [https://doi.org/10.1002/\(SICI\)1096-987X\(19991130\)20:15<1671::AID-JCC7>3.0.CO;2-Y](https://doi.org/10.1002/(SICI)1096-987X(19991130)20:15<1671::AID-JCC7>3.0.CO;2-Y)
- Lee, H.Y., Kimura, S., Iwata, T., 2019. Lipase-Catalyzed Regioselective Synthesis of Dextrin Esters. *Biomacromolecules* 20, 705–711. <https://doi.org/10.1021/acs.biomac.8b01374>
- Li, X.-J., Du, Z.-C., Huang, Y., Liu, B.-M., Hu, W.-J., Lu, W.-J., Deng, J.-G., 2013. Synthesis and hypoglycemic activity of esterified-derivatives of mangiferin. *Chin. J. Nat. Med.* 11, 296–301. [https://doi.org/10.1016/S1875-5364\(13\)60032-1](https://doi.org/10.1016/S1875-5364(13)60032-1)
- Ludwiczuk, A., Asakawa, Y., 2014. Fingerprinting of secondary metabolites of liverworts: chemosystematic approach. *J. AOAC Int.* 97, 1234–1243. <https://doi.org/10.5740/jaoacint.SGELudwiczuk>
- Maliepaard, M., de Mol, N.J., Janssen, L.H., van der Neut, W., Verboom, W., Reinhoudt, D.N., 1992. Role of lipophilicity in the *in vitro* antitumour activity of a series of new mitosene

- compounds. *Anticancer. Drug Des.* 7, 415–425.
- Novakovic, M., Bukvicki, D., Andjelkovic, B., Ilic, T.T., Veljic, M., Tesevic, V., Asakawa, Y., 2019. Cytotoxic activity of riccardin and perrottetin derivatives from the liverwort *Lunularia crucia*. *J. Nat. Prod.* 82, 694-701. DOI: 10.1021/acs.jnatprod.8b00390
- Morita, H., Zaima, K., Koga, I., Saito, A., Tamamoto, H., Okazaki, H., Kaneda, T., Hashimoto, T., Asakawa, Y., 2011. Vasorelaxant effects of macrocyclic bis(bibenzyls) from liverworts. *Bioorg. Med. Chem.* 19, 4051–4056. <https://doi.org/10.1016/J.BMC.2011.05.019>
- Osei-Safo, D., Dziwornu, G. A., Salgado, A., Sunassee, S. N., Chama, M. A., 2017. Bi- and bisbibenzyls from the roots of *Dichapetalum heudelotii* and their antiproliferative activities. *Fitoterapia* 122, 95–100.
- Otoguro, K., Ishiyama, A., Iwatsuki, M., Namatame, M., Nishihara-Tukashima, A., Kiyohara, H., Hashimoto, T., Asakawa, Y., Ōmura, S., Yamada, H., 2012. *In vitro* antitrypanosomal activity of bis(bibenzyls) and bibenzyls from liverworts against *Trypanosoma brucei*. *J. Nat. Med.* 66, 377–382. <https://doi.org/10.1007/s11418-011-0587-x>
- Polak, E., Ribiere, G., 1969. Note sur la convergence de méthodes de directions conjuguées, *Revue Française Informat. Recherche Operationelle, Serie Rouge*, 3, 35–43.
- Pretch, E., Bühlman, P., Badertscher, M., 2009. *Structure Determination of Organic Compounds*. p. 1-433. Springer, Wien. DOI 10.1007/978-3-540-93810-1
- Quang, D. N., Asakawa, Y., 2010. Chemical constituents of the Vietnamese liverwort *Porella densifolia*. *Fitoterapia* 81, 652–661.
- Rutkowska, E., Pajak, K., Kóźwik, K., 2013. Lipophilicity-methods of determination and its role in medicinal chemistry. *Acta Pol. Pharm.* 70, 3–18.
- Sarmah, N., Revathi, D., Sheelu, G., Yamuna Rani, K., Sridhar, S., Mehtab, V., Sumana, C., 2018. Recent advances on sources and industrial applications of lipases. *Biotechnol. Prog.* 34, 5–28. <https://doi.org/10.1002/btpr.2581>
- Schwartner, C., Bors, W., Michel, C., Franck, U., Müller-Jakic, B., Nenninger, A., Asakawa, Y., Wagner, H., 1995. Effect of marchantins and related compounds on 5-lipoxygenase and cyclooxygenase and their antioxidant properties: a structure activity relationship study. *Phytomedicine* 2, 113–117. [https://doi.org/10.1016/S0944-7113\(11\)80055-3](https://doi.org/10.1016/S0944-7113(11)80055-3)
- Seddigi, Z.S., Malik, M.S., Ahmed, S.A., Babalghith, A.O., Kamal, A., 2017. Lipases in asymmetric transformations: Recent advances in classical kinetic resolution and lipase–

- metal combinations for dynamic processes. *Coord. Chem. Rev.* 348, 54–70.  
<https://doi.org/10.1016/J.CCR.2017.08.008>
- Soleimani, S.S., Nadaroglu, H., Kesmen, Z., 2017. *Lactobacillus brevis* Lipase: Purification, Immobilization onto Magnetic Florosil NPs, Characterization and Application as a Detergent Additive. *Tenside Surfactants Deterg.* 54, 194–205.  
<https://doi.org/10.3139/113.110495>
- Tanaka, M., Esaki, T., Kenmoku, H., Koeduka, T., Kiyoyama, Y., Masujima, T., Asakawa, Y., Matsui, K., 2016. Direct evidence of specific localization of sesquiterpenes and marchantin A in oil body cells of *Marchantia polymorpha* L. *Phytochemistry* 130, 77–84.  
<https://doi.org/10.1016/J.PHYTOCHEM.2016.06.008>
- Wang, Z., Zhang, Y., Zheng, L., Cui, X., Huang, H., Geng, X., Xie, X., 2018. Regioselective acylation of resveratrol catalyzed by lipase under microwave. *Green Chem. Lett. Rev.* 11, 312–317. <https://doi.org/10.1080/17518253.2018.1500046>
- Yang, R., Liu, X., Chen, Z., Yang, C., Lin, Y., Wang, S., 2014. Highly Efficient and Enzymatic Regioselective Undecylenoylation of Gastrodin in 2-Methyltetrahydrofuran-Containing Systems. *PLoS One* 9, e110342. <https://doi.org/10.1371/journal.pone.0110342>
- Zhou, X.-Y., Chen, X., 2018. Na<sub>2</sub>CO<sub>3</sub>-Catalyzed O-Acylation of Phenols for the Synthesis of Aryl Carboxylates with Use of Alkyl Carboxylates. *Synlett* 29, 2321–2325.  
<https://doi.org/10.1055/s-0037-1610265>



Graphical abstract

Journal Pre-proof

### Highlights

- Chemical and enzymatic synthesis of 7 marchantin A ester derivatives were presented
- The antiproliferative activities of all prepared derivatives were tested
- MonoC6 ester exhibited similar activity and better selectivity than marchantin A
- Regioselective enzymatic monoesterification enhanced selectivity of marchantin A

Journal Pre-proof